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Simple Summary: HMGB1 over-expression is associated to prostate and ovary cancers: in this work,
using a proteomic approach, we aimed to discover new protein interactions that might contribute to
understand the oncogenic function of HMGB1 in cancers models. Our findings show that HMGB1
interacts with components of the NuRD, THOC and septin complexes, revealing new connections of
HMGB1 functions to RNA processing and ribosome biogenesis. Results might contribute to consider
the components of these interactomes as targets for diagnosis and therapy in future studies.
Abstract: This study reports the HMGB1 interactomes in prostate and ovary cancer cells lines.
Affinity purification coupled to mass spectrometry confirmed that the HMGB1 nuclear interactome
is involved in HMGB1 known functions such as maintenance of chromatin stability and regulation
of transcription, and also in not as yet reported processes such as mRNA and rRNA processing.
We have identified an interaction between HMGB1 and the NuRD complex and validated this by
yeast-two-hybrid, confirming that the RBBP7 subunit directly interacts with HMGB1. In addition,
we describe for the first time an interaction between two HMGB1 interacting complexes, the septin
and THOC complexes, as well as an interaction of these two complexes with Rab11. Analysis of
Pan-Cancer Atlas public data indicated that several genes encoding HMGB1-interacting proteins
identified in this study are dysregulated in tumours from patients diagnosed with ovary and prostate
carcinomas. In PC-3 cells, silencing of HMGB1 leads to downregulation of the expression of key
regulators of ribosome biogenesis and RNA processing, namely BOP1, RSS1, UBF1, KRR1 and
LYAR. Upregulation of these genes in prostate adenocarcinomas is correlated with worse prognosis,
reinforcing their functional significance in cancer progression.
Keywords: HMGB1 interactome; ribosome biogenesis; RNA processing; ovary cancer; prostate cancer
1. Introduction
The HMGB protein family includes both transcription factors, which regulate gene
expression by recognising specific regulatory DNA sequences in promoters, and also pro-
teins not classified as canonical transcription factors. The latter, which are considered
architectural chromatin components that bind to DNA without sequence specificity, in-
fluence transcriptional regulation and DNA repair by different mechanisms, including
nucleosome remodelling, chromatin dynamics and epigenetic modification (reviewed
in [1]). Human HMGB1 binds DNA without sequence specific recognition and the gene
encoding it, HMGB1, is overexpressed in many types of cancer [2], including those of
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prostate [3] and ovary [4]. Although HMGB1 over-expression is extensively associated to
cancer [5] and it has been demonstrated that HMGB1 silencing in colorectal cancer cells
slows cell growth, extends the cell proliferation cycle, and significantly inhibits the growth
of xenograft tumour in nude mice [6], little is known about the mechanism underlying
HMGB1’s role in oncogenesis.
Proteomic techniques allow the characterisation of protein–protein interactions and
open new insights into mechanisms of biological processes and human diseases. The role
of interactomics in expanding the advancement of biomedical science in cancer research
and therapy is well established [7]. We have previously reported interactome studies
of HMGB1 and HMGB2 proteins in prostate [8] and ovary [9] cancer cells based on the
yeast two-hybrid approach, but the number of proteins identified was low. To extend
the in vivo discovery in cancer cells, we have undertaken a different HMGB1-interactome
analysis approach based on immunoprecipitation (IP) and mass spectrometry (MS) in PC-3
and SKOV-3 cell lines that represent models for prostate and ovarian cancer, respectively.
HMGB1 has complex and diverse functions depending on its cellular location and acts
as a DNA chaperone in the nucleus, but also controls apoptosis and autophagy in the
cytoplasm, and acts extracellularly as an alarmin [2,10]. Combining IP-MS analysis with
subcellular fractionation prior to immunoprecipitation allowed us to pinpoint the cellular
localisation of the interactions identified. We found that HMGB1 interacts with components
of the NuRD complex, THOC complex and septins in the nucleus. We also identified novel
interactions between septins and the THOC complex, as well as their interaction with
Rab11. The HMGB1 interactome is enriched in proteins involved in RNA processing and
ribosome biogenesis. Interestingly, HMGB1 silencing in PC-3 cells results in dysregulation
of genes involved in these processes too, mimicking the dysregulation observed in tumours
from patients diagnosed with ovary cystadenocarcinoma and prostate adenocarcinoma
(acinar type) with lower levels of HMGB1.
2. Materials and Methods
2.1. Cell Culture
PC-3, DU-145 (human prostate cancer) and SKOV-3 (human ovarian cancer) cell lines
were grown in RPMI-1640 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and McCoy’s
5a Modified Medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented
with 10% heat-inactivated foetal bovine serum (Thermo Fisher Scientific, Inc., Waltham,
MA, USA) and 1% penicillin-streptomycin (Thermo Fisher Scientific, Inc., Waltham, MA,
USA), respectively. Cells were cultured at 37 ◦C, 5% CO2 in a humidified incubator. Cells
were tested regularly for mycoplasma contamination.
2.2. Subcellular Fractionation
Confluent SKOV-3 and PC-3 cells were pelleted down by centrifugation at 1000 rpm
(Centrifuge 5804R, A-4-44 rotor, Eppendorf, Hamburg, Germany) for 5 min and cell frac-
tionation was performed immediately. Each pellet was resuspended in Lysis Buffer (10 mM
Tris-HCl pH 8.0, 10 mM NaCl, 1.5 mM MgCl2, 0.05% NP-40) supplemented with HaltTM
Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA) and 1mM DTT just prior to use and incubated for 10 min on ice.
The lysate was then added carefully onto an equal volume of sucrose cushion (10 mM
Tris-HCl pH 8.0, 10 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 0.05% NP-40, 1.2 M sucrose),
HaltTMProtease and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scientific,
Inc., Waltham, MA, USA) and centrifuged at 4000 rpm for 10 min at 4 ◦C. After centrifuga-
tion, the supernatant containing the cytoplasmic fraction was transferred to a new tube.
The nuclear pellet was resuspended in Nuclear Extraction Buffer (50 mM Tris-HCl pH8.0,
450 mM NaCl, 1.5 mM MgCl2, 0.2% NP-40, 10% glycerol) supplemented with HaltTM-
Protease and Phosphatase Inhibitor Single-Use Cocktail (Thermo Fisher Scientific, Inc.,
Waltham, MA, USA) and 1mM DTT just prior to use, and incubated with rotation for 30
min at 4 ◦C. If the lysate was going to be used for immunoprecipitation 1.5:1000 (v/v)
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Benzonase®Nuclease (Sigma-Aldrich, St. Louis, MO, USA) was added to the Nuclear
Extraction Buffer to eliminate nucleic acids. After the incubation, the nuclear lysates were
centrifuged at 13,000 rpm at 4 ◦C for 10 min. The supernatant (soluble nuclear fraction) was
transferred to a new tube and the pellet (chromatin and membrane debris) was also stored.
To assess protein localisation, lysis buffer was added to the different cellular fractions to
equalise the volumes.
2.3. Large-Scale Immunoprecipitation
PC-3 and SKOV-3 cells were lysed in 50 mM Tri-HCl pH 8.0, 150 mM NaCl, 0.1% NP-
40, 1 mM EDTA, 2 mM MgCl2 and complete™ Mini, EDTA-free Protease Inhibitor Cocktail
(Roche, Basel, Switzerland) and incubated with 1.5:1000 (v/v) Benzonase®Nuclease (Sigma-
Aldrich, St. Louis, MO, USA) for 30 min at 4 ◦C to eliminate nucleic acids from the lysates.
Total protein was quantified using the Bradford method. In total, 40 µg of HMGB1 antibody
(Abcam, ab 18256, Cambridge, UK), THOC5 antibody (Abcam ab86070) or anti-rabbit IgG
antibody (Millipore, Co., Burlington, MA, USA) were crosslinked to 50 µL of Protein G-
Dynal beads (Invitrogen, Waltham, MA, USA) as previously described [11]. For each IP,
2.5–3 mg of total protein were incubated with antibody-coupled beads for 4 h at 4 ◦C and
beads were then washed four times with IPP150 buffer (10 mM Tris-HCl pH 8.0, 150 mM
NaCl and 0.1% NP-40) and four times with 50 mM ammonium bicarbonate. On-bead
digestion was carried out as previously described [12].
2.4. Mass Spectrometry and Data Analysis
Peptides from large-scale IPs were analysed with online nanoLC-MS/MS on an Orbi-
trap Velos mass spectrometer coupled with an Ultimate 3000 RSLCnano System. Samples
were first loaded and desalted on a nanotrap (100 µm id × 2 cm) (PepMap C18, 5 µ) at
10 µL/min with 0.1% formic acid for 10 min and then separated on an analytical column
(75 µm id× 25 cm) (PepMap C18, 2µ) over a 120 min linear gradient of 4–32% CH3CN/0.1%
formic acid at 300 nL/min, and the total cycle time was 150 min. The Orbitrap Velos was
operated in standard data-dependent acquisition. The survey scans (m/z 380–1500) were
acquired in the Orbitrap at a resolution of 30,000 at m/z 400, and one micro-scan was
acquired per spectrum. The 10 most abundant multiply charged ions with a minimal
intensity of 2000 counts were subject to MS/MS in the linear ion trap at an isolation width
of 2 Th. Dynamic exclusion width was set at ±10 ppm for 45 s. The automatic gain control
target value was regulated at 1 × 106 for the Orbitrap and 5000 for the ion trap, with
maximum injection time at 200 ms for Orbitrap and 100 ms for the ion trap, respectively.
The raw files were processed with Proteome Discoverer v1.4 (Thermo Fisher Scientific,
Inc., Waltham, MA, USA). Database searches were performed with Mascot (Matrix Science,
Inc., Boston, MA, USA) against the human Uniprot database (2014, 77,606 entries) and an
in-house contaminant database. The search parameters were trypsin/P digestion, 2 missed
cleavages, 10 ppm mass tolerance for MS, 0.5 Da mass tolerance for MS/MS, with vari-
able modifications of acetyl (N-terminal), carbamidomethyl (C), N-formylation (protein),
oxidation (M), and pyro-glu (N-term Q). Database search results were refined through
processing with Percolator (significance threshold < 0.05, FDR < 1%). Protein identification
required at least one high-confidence peptide (FDR < 1%) with a minimum score of 20.
External contaminants (albumin, casein, trypsin) were removed from protein lists before
further analysis. Keratins were not removed, as they could potentially represent true
interactors. To discriminate specific from non-specific interactions, the identified proteins
in each IP (specific antibody as experiment and IgG antibody as negative control) were
analysed with the Significance Analysis of INTeractome (SAINT) score SAINTexpress [13].
Results from each experiment were analysed using their corresponding negative control.
Preys with SAINT probability score cut-off of 0.7 detected by at least two unique pep-
tides were deemed high confidence HMGB1 interacting proteins and further analysed for
biological significance. The mass spectrometry proteomics data have been deposited to
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the ProteomeXchange Consortium via the PRIDE [14] partner repository with the dataset
identifier PXD026258.
2.5. Yeast Two-Hybrid Assays








Once amplified, the genes were cloned in pGAD-C2 and pGBD-C2 vectors (15), re-
spectively. These vectors allow expression of HMGB1 and RBBP7 proteins fused to the
domains Gal4-AD (Activation domain) or Gal4-BD (DNA binding domain) of the yeast
transcriptional activator Gal4. The expression of the fused genes is controlled by the ADH1
gene promoter. For yeast-two hybrid assays both constructs were co-transformed into the
two-hybrid host strain PJ69-4A (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4∆ gal80∆
LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ) developed by James et al. [15], which
allows the use of three reporter genes induced by Gal4 (HIS3, ADE2, lacZ) for assess-
ing protein–protein interactions. Yeast transformants were selected in minimal complete
medium (CM) without Trp and Leu and positive candidates were selected after growing
them in CM without His and CM without Ade and testing them for β-galactosidase activ-
ity. β-galactosidase activity was measured following the method developed by Rose and
Botstein [16] using ONPG as substrate. In total, 150 µL of total protein was mixed with
850 µL of Z Buffer (40 mM Na2HPO4, 60 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50
mM 2-Mercaptoethanol). After incubation at 28 ◦C for 5 min, 200 µL of 4 mg/mL ONPG in
Z buffer were added. Reaction was stopped by addition of 500 µL 1 M Na2CO3 when a
colour change was spotted, and reaction time was written down. Absorbance measures
were taken at 420 nm. Specific activity was calculated as (A420 × 1.7)/(0.0045 × protein
concentration × extract volume × time). Protein concentration is measured in mg/mL,
extract volume in mL and time in minutes.
2.6. Small Scale Immunoprecipitation and Western Blot
PC-3 lysates were obtained as described above. A total of 25 µL of beads were
coupled with 5 µg of antibody. Antibodies were not crosslinked to protein G-Dynal beads
(Invitrogen). IPs were carried out with Abcam antibodies to THOC5 (ab86070), THOC2
(ab129485), RAB11 (ab3612), and Millipore Normal Rabbit IgG Polyclonal (12–360) was
used as the negative control. Then, 1 mg of total protein was used for each IP. Proteins were
eluted by incubation in 1× LDS loading buffer (Life Technologies, Carlsbad, CA, USA)
containing 350 mM beta-mercaptoethanol at 95 ◦C for 10 min.
For Western blot, protein samples were run on NuPAGE 4–12% Bis-Tris Protein Gels
(Novex, Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 50 min at 200 V and trans-
ferred onto a nitrocellulose or PVDF membrane at 30 V for 1 h. Membranes were blocked
with PBS-0.1% Tween-20 (PBST) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, 0.1% Tween-20) containing 5% non-fat milk for 1 h at room temperature or at
4 ◦C overnight. Membranes were then incubated with the primary antibody: anti-GAPDH
(Santa Cruz Biotechnology, Dallas, TX, USA, sc-25778, 1/2000), anti-RBBP4 (Abcam ab1765,
1/4000), anti-Histone3-Lys14acetylated (Millipore, Co., Burlington, MA, USA, 07-353,
1/2000), anti-THOC5 (Abcam, Cambridge, UK, ab86070, 1/1000), anti-THOC2 (Abcam
ab129485, 1/1000), anti-SEPT7 (Abcam, Cambridge, UK, ab186021, 1/1000), anti-SEPT2
(Abcam, Cambridge, UK, ab18020, 1/1000) for 1 h at RT or with anti-HMGB1 (Santa Cruz
Biotechnology, Dallas, TX, USA, sc-74085, 1/1000) and anti-RAB11 (Abcam, Cambridge,
UK, ab3612, 1/1000), at 4 ◦C overnight. After washing with PBST, membranes were
Cancers 2021, 13, 4686 5 of 18
probed with the corresponding horseradish peroxidase-conjugated secondary antibodies:
anti-protein G, HRP conjugate (Millipore, Co., Burlington, MA, USA, 18–161, 1/5000) or
anti-rabbit HRP (1/2000). After washing the membranes with PBST, chemiluminescence
analysis was performed using Amershan-TMECLTM-Prime Western blotting detection
reagents according to the manufacturer’s instructions. X-ray films or Bio-Rad ChemiDocTM
imager were used for chemiluminescence detection.
2.7. HMGB1 Silencing
siRNAs directed against HMGB1 (siRNA-HMGB1: s20254 Silencer Select) and unspe-
cific control (siRNAControl2: 4390846) were purchased from Ambion Inc. (Thermo Fisher
Scientific, Inc., Waltham, MA, USA). Transfection of cells and verification of mRNA and
HMGB1 protein downregulation by qRT-PCR and Western blot were done as previously
described [9].
2.8. qPCR Analysis of Gene Expression
RNA samples from PC-3 and DU-145 cell cultures were obtained using GeneJET RNA
Purification Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Reaction conditions
for thermal cycling and relative expression calculation were already described [9].
The following primers were used for qPCR amplification. KRR1, 5′-CCAAAGAGGAC
AATCCCAGAG-3′ and 5′-TGTTCATTTAAGGCTTTCTGCAC-3′; BOP1, 5′-CGAGATCTGG
GAGTGCTGGA-3′ and 5′-CTAGGTGAAGAGGCGA CAGTC-3′; RRS1, 5′-TGAACAGCAA
GAAGCCTCAGC-3′ and 5′-CCCTTCTGGCT CATTTTCCTC-3′; LYAR, 5′-GCAAGGGGAG
GTGAAGAAGAA-3′ and 5′-GGCTTCTGATTCCTTGAGTTTTC-3′; UBTF, 5′-CTCGGAGG
AGAAACGGCG-3′ and 5′-TTCTCAGACAGGTCGTTCCACA-3′.
3. Results
3.1. HMGB1 Interactome in Ovary and Prostate Cancer Cell Lines
To increase our understanding of HMGB1 cellular functions in cancer cells, we profiled
HMGB1 interactomes in SKOV-3 and PC-3 cancer lines from ovarian and prostate tumours,
respectively, by affinity purification followed by mass spectrometry (AP-MS). We carried
out three independent HMGB1 immunoprecipitation experiments and corresponding
isotype IgG controls from whole cell extracts of each cell line, which identified 109 and
50 HMGB1 interacting proteins in SKOV-3 and PC-3 cells, respectively (Tables S1 and S2). In
addition, we also performed one replicate AP-MS experiment from nuclear and cytoplasmic
extracts separately in each cell line with their corresponding IgG controls. Subcellular
fractionation was verified by Western blot (Figures 1A and S3). This allowed us not only
to map interactions to the nuclear and cytoplasmic compartments, but also enabled the
detection of a higher number of HMGB1 interacting partners to those detected in whole cell
lysates. The majority of interactions were identified in the nuclear fraction, in agreement
with HMGB1′s main cellular localisation [17]. We identified 306 and 289 interactions in
the nuclear fractions of SKOV-3 and PC-3 cells respectively (Tables S3 and S4), compared
to 117 and 76 interactions (Tables S5 and S6) in the corresponding cytoplasmic fractions
(Figure 1B). Over 50% of identified proteins were common to PC-3 and SKOV-3 cells
(Figure 1C). Comparison with the BioGrid interaction database (https://thebiogrid.org,
accessed on 20 February 2021) revealed that 140 out of 438 total interactions (32%) identified
in our study had already been reported in mammalian cells (Figure 1D), indicating that
our AP-MS approach is able to capture known HMGB1 interactions and reinforcing the
reliability of the novel interactions discovered in our study.
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Figure 1. HMGB1 interactome. (A) Western blot verification of cellular fractionation of SKOV-3 and PC-3 lysates: nuclear –N-
and cytoplasmic –C- fractions and residual pellet –P- were separated in polyacrylamide gels and hybridised against GADPH
antibody or H3K14-Ac antibody. (B) Venn diagram that summarises the distribution of HMGB1 interactions detected in
nuclear and cytoplasmic fractions of SKOV-3 and PC-3 cell lines. (C) Venn diagram remarking common interactions detected
in SKOV-3 and PC-3 cells. (D) Venn diagram showing the intersection of proteins detected in the HMGB1-interactomes
with other previously reported HMGB1 binding proteins (https://thebiogrid.org/, accessed on 20 February 2021).
GO-term enrichment analyses were carried out on HMGB1 associated proteins de-
tected in whole-cell lysates (Table 1), as well as nuclear or cytoplasmic fractions of SKOV-3
and PC-3 cells (Table 2 and Figure S1). As expected from previous reports on HMGB1 func-
tions (5, 10), in the nuclear interactome we observed an enrichment of proteins associated
with the GO-terms chromatin organisation, nucleosome organisation, epigenetic regulation
of gene expression and DNA repair. In addition, an important fraction of proteins detected
in the nuclear HMGB1 interactome are functionally connected to RNA processing of differ-
ent rRNAs, mRNA splicing via spliceosome, ribonucleoprotein (RNP) complex biogenesis
and RNP export from nucleus. In the cytoplasmic interactome, we observed enrichment of
the GO-terms translation, SRP-dependent co-translational protein targeting to membrane,
regulation of translation, and cell division.
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Table 1. GO term enrichment analysis of the whole lysate in HMGB1-interactomes in SKOV-3 and PC-3 cells. (OGC,
observed gene count; BCG, background gene count; FDR, false discovery rate; ns, not statistically significant).
SKOV-3 PC-3
ID Description OGC BGC FDR OGC BGC FDR
GO:0000445 THO complex part of TREX 4 6 2.04 × 10−6 4 6 2.64 × 10−7
GO:0006396 RNA processing 54 825 6.15 × 10−41 ns
GO:0000398 mRNA splicing, via spliceosome 35 284 1.91 × 10−33 14 284 6.00 × 10−12
GO:0006364 rRNA processing 8 192 0.00024 ns
GO:1990904 Ribonucleoprotein complex 39 770 5.65 × 10−25 13 770 8.23 × 10−7
GO:0022613 RNP complex biogenesis 20 409 8.51 × 10−12 8 409 0.00038
GO:0000387 Spliceosomal snRNP assembly 4 37 0.0010 ns
GO:0071426 RNP complex export from nucleus 20 124 9.01 × 10−21 ns
GO:0006325 Chromatin organisation 13 683 0.0016 ns
GO:0034728 Nucleosome organisation 7 167 0.00074 ns
GO:0040029 Regulation of gene expression,epigenetic ns 6 251 0.0016
GO:0016581 NuRD complex 2 14 0.0187 2 14 4.00 × 10−3
GO:0031105 Septin complex 4 6 2.04 × 10−6 4 6 2.64 × 10−7
GO:0051301 Cell division 10 483 0.0049 9 483 1.7 × 10−4
GO:0006614 SRP-dependent cotranslationalprotein targeting to membrane 11 92 3.44 × 10
−10 ns
GO:0002181 Cytoplasmic translation 4 57 0.0044 ns
GO:0006417 Regulation of translation 7 327 0.0258 ns
IPR016491 Septin 8 13 1.03 × 10−11 8 13 3.40 × 10−14
Table 2. GO term enrichment analysis of the nuclear and cytoplasmic HMGB1-interactomes in SKOV-3 and PC-3 cells.
(OGC, observed gene count; BCG, background gene count; FDR, false discovery rate).
SKOV-3 PC-3
ID Description OGC BGC FDR OGC BGC FDR
NUCLEUS
GO:0006396 RNA processing 119 825 6.10 × 10−75 100 825 3.72 × 10−59
GO:0000398 mRNA splicing, via spliceosome 65 284 7.83 × 10−50 41 284 1.94 × 10−25
GO:0006364 rRNA processing 43 192 3.72 × 10−32 51 192 3.54 × 10−43
GO:0000470 Maturation of LSU-rRNA 12 24 2.69 × 10−12 14 24 1.87 × 10−15
GO:0030490 Maturation of SSU-rRNA 12 52 4.08 × 10−9 15 52 5.52 × 10−13
GO:0000460 Maturation of 5.8S rRNA 4 32 0.0196 9 32 1.21 × 10−6
GO:1990904 Ribonucleoprotein complex 149 770 9.45 × 10−115 141 770 2.47 × 10−110
GO:0022613 RNP complex biogenesis 81 409 1.37 × 10−58 79 409 3.94 × 10−59
GO:0000387 Spliceosomal snRNP assembly 10 37 3.27 × 10−8 7 37 3.70 × 10−5
GO:0051169 Nuclear transport 28 267 3.38 × 10−13 27 267 3.59 × 10−13
GO:0071426 RNP complex nuclear export 18 124 1.37 × 10−10 17 124 3.49 × 10−10
GO:0006325 Chromatin organisation 42 683 2.47 × 10−12 40 683 3.67 × 10−12
GO:0034728 Nucleosome organisation 22 167 3.66 × 10−12 22 167 3.66 × 10−12
GO:0040029 Regulation of gene expression,epigenetic 21 251 2.45 × 10
−8 17 251 4.77 × 10−6
GO:0016581 NuRD complex 6 14 3.05 × 10−6 5 14 4.20 × 10−5
GO:0031105 Septin complex 4 6 6.96 × 10−5 4 6 5.79 × 10−5
GO:0006281 DNA repair 19 491 0.0039 15 491 0.0440
GO:0051301 Cell division 21 483 0.00036 24 483 4.47 × 10−6
CYTOPLASM
GO:0006614 SRP-dependent cotranslationalprotein targeting to membrane 60 92 2.15 × 10
−96 29 92 2.53 × 10−43
GO:0002181 Cytoplasmic translation 27 57 6.52 × 10−39 13 57 1.72 × 10−17
GO:0006417 Regulation of translation 12 327 1.39 × 10−5 11 327 1.31 × 10−6
GO:0051301 Cell division 11 483 0.0025 12 483 6.70 × 10−6
IPR016491 Septin 8 13 4.74 × 10−11 8 13 1.06 × 10−12
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Interaction network analysis of the HMGB1 interactomes obtained from SKOV-3 and
PC-3 cell lysates with STRING [18] revealed three interesting clusters that corresponded
to components of the NuRD and THOC nuclear complexes, as well as the septin complex
(Figure 2).
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chromatin organisation (GO:0006325); purple cell division (GO:0051301); brown, DNA repair (GO:0006281); dark green,
NuRD complex (GO:0016581).
3.2. HMGB1 Interacts with Nucleosome Remodelling (NuRD) Complex Subunit RBBP7
We repeatedly identified several subunits (MTA2, CHD4, RBBP4, HDAC1, RBBP7,
HDAC2) of the NuRD complex in HMGB1 IP experiments in both whole cell lysates and
nuclear fractions from SKOV-3 and PC-3 cells (Tables S1–S4). CHD4, MTA2, HDAC1/2
were only detected in nuclear interactomes, whilst RBBP4 and RBBP7 were detected in both
whole cell and nuclear interactomes, together with ZNF512B, which is a substoichiometric
interactor of the NuRD complex [19]. CHD4 was only detected in the SKOV-3 cell line.
The NuRD complex has been associated to transcriptional processes, chromatin assembly
mechanisms, cell cycle progression, genomic stability and epigenetic control of gene expres-
sion [20]. Despite being involved in the same processes, no previous interactions between
HMGB1 and NuRD complex subunits have been reported. To validate this association, we
tested for a direct physical interaction using the yeast two-hybrid assay [15]. We selected
for this assay two candidates in the complex, RBBP4 and RBBP7, dynamic core subunits of
the NuRD complex, which act as histone chaperones [19]. We confirmed a direct physical
association between HMGB1 and RBBP7 (Figure 3A), demonstrating that these proteins do
indeed interact. We did not detect an interaction with RBBP4 (data not shown), suggesting
that RBBP4 might be linked to HMGB1 through RBBP7.
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Figure 3. (A) Validation of the HMGB1-RBBP7 interaction by the two-hybrid approach. (B) Differential mRNA levels of
NuRD complex subunits in normal and cancerous ovary and prostate cell lines. (C) Differential mRNA levels of NuRD
complex subunits in tumours and adjacent normal tissue in patients diagnosed of ovary and prostate cancers. (D) Analysis
of disease-free progression in patients with mRNA levels of NuRD subunits higher (altered group) or lower (unaltered
group) than mean + 2SD. In (B–D) the upper part is from ovary cancer and lower part from prostate cancer. The source of
data used in the analyses B-D is detailed in the text.
Since HMGB1 overexpression has been associated to cancer in different cell types [2–4]
we looked for evidence of overexpression of the NuRD complex in cancerous cells. Data
available through Expression Atlas, Cancer Cell Line Encyclopedia (Figure 3B) showed
higher mean values of mRNA expression levels of components of the NuRD complex in
different cancer cell lines (including SKOV-3 and PC-3) than in the corresponding non-
cancer cells from ovary (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-5214/Results,
accessed on 3 March 2021 and prostate (https://www.ebi.ac.uk/gxa/experiments/E-
MTAB-3358/Results, accessed on 3 March 2021)
Data from the Pan-Cancer Analysis of Whole Genomes (PCAWG) project also showed
(Figure 3C) higher mean values of mRNA expression in tumours than in adjacent normal
tissue from patients (https://www.ebi.ac.uk/gxa/experiments/E-MTAB-5200/Results,
accessed on 3 March 2021). Concomitantly, using the tools and statistics available through
cBioportal (http://www.cbioportal.org/, accessed on 3 March 2021) we found a positive
correlation between high levels of expression of five components of the NuRD complex
(RBBP4, RBBP7, HDAC1, HDAC2 and MTA2) and a shorter progression free survival, with
a logrank test p-value of 0.018, in the prostate adenocarcinoma (acinar type) study (TCGA
PanCancer Atlas), integrated by 494 patients (Figure 3D). We did not, however, observe
a statistically significant effect in the ovarian serous cystadenocarcinoma study (TCGA
PanCancer Atlas), integrated by 585 patients (Figure 3D).
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3.3. HMGB1-Associated THOC and SEPTIN Complexes Interact between Them and with RAB11
In both HMGB1 prostate and ovarian cytoplasmic and nuclear interactomes we de-
tected an enrichment of the septin complex, composed of SEPT6, SEPT9, SEPT7, SEPT11,
SEPT10, SEPT8, and SEPT2 (Figure 2). In the course of our study a physical interaction be-
tween SEPT9 and HMGB1 in cervix cancer was reported [21] further validating our results.
Septins are most commonly known as cytoskeleton GTP binding proteins [22] but have
recently also been reported as nuclear proteins involved in RNA processing [23]. We also
noticed an enrichment of the THOC complex (THOC1, THOC6, THOC5, THOC2) in the
nuclear interactomes. THOC is a subcomplex of the “transcription/export” complex (TREX
complex) [24] and its structure in humans has recently been resolved by cryo-electron
microscopy, revealing a hub for multivalent interactions [25]. This raised the question of
whether these two complexes interact. In order to explore this hypothesis, we carried out
THOC5 immunoprecipitation from PC-3 cells, followed by MS analysis. In total, 282 pro-
teins were identified as confident THOC5 interacting proteins (Table S7), several of which
we had identified also as HMGB1 binding partners (Figure 4A). Among THOC5 interacting
partners we detected other THOC proteins (THOC1, THOC2, THOC3, THOC6 and THOC7)
as expected, as well as septin proteins (SEPT2, SEPT7, SEPT9 and SEPT11). In order to
verify these interactions, we carried out small scale immunoprecipitations from PC-3 cell
lysates followed by Western blotting with antibodies against THOC5, THOC2, SEPT2,
SEPT7 (Figure 4B). These experiments confirmed the physical interactions between THOC5
and THOC2, THOC2 and SEPT2, and THOC2 and SEPT7. We did not detect HMGB1 in
THOC or SEPT immunoprecipitations; this could be due to HMGB1 representing only a mi-
nor undetectable fraction of proteins interacting with the septin and THOC complexes, or
antibody-mediated displacement issues. We also probed the blots with an antibody against
the small GTPase RAB11, since this protein was identified in both HMGB1 and THOC5
interactomes in prostate cancer cells (Figure 4A, Tables S2 and S4). A band corresponding
to RAB11 was clearly detected in THOC2 and THOC5 immunoprecipitates. In addition,
we could also detect SEPT2 and SEPT7 in RAB11 immunoprecipitates (Figures 4B and S3).
These results indicate that the septin and THOC complexes interact between them and
with RAB11.
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3.4. Clinical Significance of Expression Changes of HMGB1 Interactome Components Related to
RNA Processing and Nuclear Export in Prostate and Ovary Cancers
We next analysed whether mRNA expression levels of HMGB1 and its interactome
partners in ovary and prostate tumours are correlated. To perform these analyses, we used
the tools and statistics of cBioportal (https://www.cbioportal.org, accessed on 3 March
2021) and defined two groups of samples in the prostate and ovary cancer studies of the
TCGA Pan Cancer Atlas; one group composed of samples with HMGB1 mRNA levels
lower than mean − 1.5 standard deviation (HMGB1-low) and a second group expressing
mRNA levels higher than mean + 1.5 standard deviation (HMGB1-high) (Figure 5A). After
differential gene expression analysis between the two groups, we found 31 and 79 genes (in
prostate adenocarcinoma and ovary cystadenocarcinoma, respectively) encoding HMGB1-
interacting proteins, which were more highly expressed in the HMGB1-high group with
statistical significance according to the cBioportal analysis record (Figure 5B). GO term
enrichment analysis of genes expressed at higher levels in the tumours classified as HMGB1-
high (Figure 5C) showed that these include the functional terms rRNA processing, RNP
biogenesis, mRNA splicing, and RNA export from nucleus to cytoplasm. In agreement
with these functions, the cellular compartment GO terms nucleolus and nuclear speckles
were also enriched. Indeed, we noticed that both the nuclear and cytoplasmic HMGB1
interactomes contained a high proportion of proteins previously described as part of the
RNA interactome in Hela cells (26) and that many nuclear HMGB1-interacting proteins (119
in SKOV-3 and 100 in PC-3 cells) were related to RNA processing. HMGB1 has traditionally
been considered as a non-histone chromatin protein. Therefore, we explored in more detail
their nuclear distribution using cellular component GO-term annotations (Table 3). We
confirmed that although approximately 25% are associated to chromatin structural and
modifier components, a higher proportion, 32–39%, is associated to nucleolus, where rRNA
transcription and processing occurs, as well as to spliceosome (14–22%), and mostly to
catalytic step 2 of the spliceosome mRNA processing pathway during intron elimination.
Approximately 14–20% are associated to nuclear speckles and 6–7% are associated to
nuclear membranes. Among KEGG pathways identified, we found hsa03040 (Spliceosome),
hsa03008 (Ribosome biogenesis in eukaryotes), hsa03013 (RNA transport).
A detailed distribution of selected proteins from the nuclear interactomes of SKOV-3
and PC-3 cells involved in the RNA processing and export pathway is shown in Figure 6.
These results suggest that HMGB1 could have an as yet unreported role in ribosome
biogenesis and/or splicing. To explore the biological relevance of this observation, we
obtained the list of genes that are synthetic lethal with HMGB1 from DepMap (https:
//depmap.org, accessed on 19 July 2021). The top 100 HGMB1-dependent CRISPR gene set
was enriched in genes involved in ribosome biogenesis (adj. p-value 1.82 × 10−2), rRNA
processing (adj. p-value 1.87 × 10−2) and mRNA transport (adj. p-value 2.59 × 10−2), and
genes coding for RNA-binding proteins (adj. p-value 3.11 × 10−7), further reinforcing a
role for HMGB1 in these processes.
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Figure 5. Differential expression of genes related to RNA processing in tumours expressing HMGB1 at high or low levels.
(A) Selection of samples expressing mRNA HMGB1 at levels > median + 1.5 SD (HMGB1-high) and samples expressing
mRNA HMGB1 at levels < median − 1.5 SD (HMGB1-low). (B) Volcano plots of genes expressing at higher levels in each
group; log ratio in HMGB1-high/HMGB1-low. Ov, samples obtained from the PanCancer ovarian cystadenocarcinoma
ATCG study in cBioportal; Pr, samples obtained from the PanCancer prostate adenocarcinoma ATCG study in cBioportal.
(C) GO term enrichment an lysis of genes expressed at igher levels in HMGB1-high samples in ovary or prostate cancer.
Table 3. GO-term enrichment analysis of the nuclear compartment distribution of HMGB1-nuclear interactomes in SKOV-3
and PC-3 cells. (OGC, observed gene count; BCG, background gene count; FDR, false discovery rate).
SKOV-3 PC-3
ID Description OGC BGC FDR OGC BGC FDR
GO:0005634 Nucleus 243 6892 7.34 × 10−55 226 6892 1.96 × 10−51
GO:0005654 Nucleoplasm 192 3446 5.34 × 10−66 165 3446 1.45 × 10−50
GO:0005730 Nucleolus 79 926 2.50 × 10−33 88 926 9.18 × 10−44
GO:0016604 Nuclear body 63 742 5.02 × 10−26 47 742 8.81 × 10−16
GO:0005694 Chromosome 60 950 1.13 × 10−18 60 950 2.48 × 10−20
GO:0005681 Spliceosomal complex 53 187 1.13 × 10−44 33 187 6.24 × 10−23
GO:0016607 Nuclear speck 47 381 2.12 × 10−25 32 381 9.22 × 10−14
GO:0071013 Catalytic step 2 spliceosome 43 99 1.68 × 10−42 27 99 5.63 × 10−23
GO:0000785 Chromatin 35 489 3.15 × 10−12 36 489 7.64 × 10−14
GO:0000790 Nuclear chromatin 25 333 2.75 × 10−9 24 333 4.31 × 10−9
GO:0000786 Nucleosome 17 106 7.01 × 10−11 15 106 2.51 × 10−9
GO:0005635 Nuclear envelope 16 446 0.0079 15 446 0.0118
GO:0000118 Histone deacetylase complex 8 60 6.32 × 10−5 7 60 0.00028
GO:0016581 NuRD complex 6 14 3.05 × 10−6 5 14 4.20 × 10−5
GO:0031105 Septin complex 4 6 6.96 × 10−5 4 6 5.79 × 10−5
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Figure 6. Mapping of HMGB1 interacto e to the RNA proces ing and export pathways (adapted from the KEGG map
RNA TRANSPORT from Kanehisa laboratories hsa03013, ac es ed 2 July 2020). Red, proteins found in SKOV-3; blue, in
PC-3; black, in both cell lines. The graph in the bottom right box shows the total number proteins identified and those
common to the RNA interactome described in HELA cells [26].
e also l c i g the proteins found in the HMGB1 inter-
actomes are more frequently highly expressed in tumour samples from prostate adeno-
carcinomas, and we found among them RRS1 and BOP1, both important regulators of
ribosome biogenesis. In order to as ess how HMGB1 expre sion affects e , the
GB1 gene as silenced by iR approach as previously described (8) in the prostate
cel lines PC-3 and D -145 (Figure 7 ). Levels of expression of RRS1, BOP1, as wel as
KRR1, LYAR and UBTF, also implicated in the control f ribos me biogenesis and found in
our interactome study, were measured in silenced and control cells (Figure 7A). Results
sho ed that expression levels of all candi ates except KRR1 were lower in one r both cell
lines when HMGB1 was silenced (Figure 7B). A percentage of adenocarcinoma tu ours
show high expression of these ribosome biogenesis genes (Figure 7C). In addition, higher
expression of these genes was associated to shorter progression-free survival (logrank
test p-value 1.57 × 10−2) in patients (Figure 7D). To explore whether a correlation exists
between the expression of genes related to RNA processing/RNA nuclear export, and
clinical outcome of patients with prostate or ovary tumours, we also analysed survival data
available in TCGA Pan Cancer Atlas through cBioportal. In the prostate adenocarcinoma
study we found that higher expression of these genes was positively correlated with worse
progression-free survival for LSU-rRNA (logrank test p-value 7.11× 10−3), 5.8S rRNA from
tricistronic rRNA transcript (logrank test p-value 6.19 × 10−3), RPN complex assembly
(logrank test p-value 5.73 × 10−3), mRNA splicing at catalytic step 2 (logrank test p-value
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5.51 × 10−3), and nucleo-cytoplasmic transport (logrank test p-value 1.08 × 10−3) related
genes (Figure S2). This correlation was not found in ovary cystadenocarcinoma.
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survival, and tumorigenesis [27], and we have found a positive correlation between higher 
Figure 7. Effects of HMGB1 silencing on gene expression. (A) Verification of HMGB1 silencing by qPCR. (up) and Western
blot (down); * p < 0.05, * p < 0.001 ( ) ff cts t expression of genes with regulatory functions in
RNA processing and/or ribosome biogenesis. (C) Percentage of d n carcinom tumours with high expression (mean+2SD)
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Together, these data suggest that HMGB1 has a role in ribosome biogenesis through
interaction with and regulation of expression of genes involved in this process, with
significant clinical impact in cancer patients.
4. Discussion
The functions associated to proteins interacting with HMGB1 in nucleus and cyto-
plasm repor ed in our stu y provide new clues shedding light o the contribution of
HMGB1 to prostate and ovary ncoge esis. The id ntification of common interactors of
HMGB1 in PC-3 and SKOV-3 cells lin s is noteworthy and might suggest that th onc genic
role of HMGB1 overexpression affects basic cellular functions t at are altered in different
cancers. Previous data on HGMB1 functions pointed to its involvement in DNA related
processes, like replication, transcription and DNA repair, as well as in apoptosis/autophagy
balance and extracellular signalling [5]. Our interactome investigation has revealed novel
HMGB1 binding partners which strongly associate HMGB1 function with RNA metabolic
processes, such as rRNA transcription and processing, mRNA processing in the spliceo-
some, RNA and RNP transport from nucleus to cytoplasm and ribosome assembly. These
processes have great importance in cell proliferation, differentiation, cell survival, and
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tumorigenesis [27], and we have found a positive correlation between higher expression of
HMGB1 interacting proteins with worse patient prognosis in prostate cancer. Since cancer
development demands a higher rate of cell division and metabolism, which requires an
increase in protein synthesis, alterations in ribosomal proteins networks necessarily play a
role in tumour development. Importantly, other HMGB proteins of different origins from
yeast to human have previously been associated with ribosome biogenesis [28].
A significant number of proteins characterised in our interactome, including HMGB1,
were previously identified as RNA-binding proteins in cancer cells [26]. This is remarkable
since some RNA-binding proteins are also known as post-transcriptional drivers of cancer
progression [29]. This characteristic, together with their functions in the RNA processing
and ribosome biogenesis pathways suggest that HMGB1 might connect the transcription
of specific pre-rRNAs and pre-mRNAs to their processing, nucleo-cytoplasmic export and
final participation in translation, via protein–protein interactions.
Supporting this hypothesis, we found a positive correlation between increased HMGB1
gene expression and increased expression of genes involved in these processes, both in
ovary cystadenocarcinoma and prostate adenocarcinoma tumours. In addition, we verified
that HMGB1 silencing causes a downregulation of genes participating in rRNA processing
and ribosome biogenesis (RRS1, BOP1, as well as of KRR1, LYAR and UBTF in PC-3 and/or
DU-145 cells). RSS1 controls ribosome biogenesis through the 5S RNP complex, composed
of rRNA 5S, RPL5 and RPL11 (proteins also identified in the present HMGB1 interactome)
and is responsible for their nucleolar localisation [30]. It has been reported that higher levels
of RSS1 and BOP1 are observed in 14% and 8%, respectively, of prostate adenocarcinomas
and that higher levels of RRS1 mRNA correlate with shorter progression-free periods.
BOP1 knockdown results in decreased proliferation and motility [31], implicating this
gene in prostate cancer aggressiveness. UBTF is a HMGB-box factor whose depletion
causes apoptotic death in transformed cells [32] and is involved in RNA Pol I transcription
and regulation of highly transcribed RNA Pol II genes [33]. KRR1 is related to pre-40S
subunit assembly during ribosome biogenesis [34], and LYAR is involved in formation
of pre-rRNAs and their subsequent processing to produce 18S and 28S rRNAs [35] and
pre-ribosome assembly [36].
We also detected an interaction of HMGB1 with components of several protein com-
plexes related to rRNA synthesis and ribosome biogenesis, namely NuRD, THOC and
septin complexes.
We show that in the nucleus HMGB1 interacts with several subunits of the NuRD
complex prominently in nuclear fractions, and we confirmed its direct physical interaction
with RBBP7. In growth-arrested and differentiated cells the NuRD complex is strongly
associated to rRNA genes (rDNA) and maintains them in a silent state characterised by
methylation and heterochromatic features [37]. The discovered interaction between HMGB1
and RBBP7 could be a factor modifying the silenced state and increasing rRNA synthesis.
THOC1, THOC2, THOC5 and THOC6, members of the THO subcomplex of TREX [38]
which participates in mRNA processing and transport of RNPs from nucleus to cytoplasm,
are present in HMGB1 immunoprecipitates from ovary and prostate cancer cells. THOC1
has previously been associated to prostate cancer aggressiveness [39]. THOC5 is highly
specialised in the processing of mRNAs related to cancer proliferation, since it contributes
to more than 90% of the 3′ processing and/or export of immediate-early genes induced
by growth factors and/or cytokines, but only to less than 1% of total mRNA export in the
steady state [40,41]. This reinforces our hypothesis that HMGB1 interactions orchestrate the
transcription of specific pre-rRNAs and pre-mRNAs to their processing, nucleo-cytoplasmic
export and final participation in translation.
Septins, a family of GTP-binding proteins which participate in a spectrum of cellular
processes including cytokinesis, cilliogenesis, cell migration, polarity, and cell–pathogen
interactions [22,42] were also identified in the HMGB1 interactomes. Surprisingly, in a
previous interactome analysis of septins [23], the most significant connections were found
with RNA splicing and processing, an unprecedented observation despite extensive prior
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work on septins. Since both the THOC complex [43] and several septins [23] have been
related to nuclear speckles, we decided to look for an interaction between components
of the THOC complex and septins in prostate cancerous cells. In the IP-MS experiments
carried using THOC5 antibody we identified other components of the THOC complex
as well as SEPT2, SEPT7, SEPT9 and SEPT11. Cross validation in PC-3 cell lysates by
co-immunoprecipitation confirmed the physical interactions between THOC5 and THOC2,
THOC2 and SEPT2, THOC2 and SEPT7. The small GTPase, RAB11, another HMGB1-
interacting protein from our IP-MS experiments, also immunoprecipitated with HMGB1
and THOC5. All these data reinforce the function of septins in RNA splicing and processing
as well as the involvement of HMGB1 in these functions. It is worth remarking that septins
have been linked to cancer, specifically SEPT9 to prostate cancer [44]. In the course of our
study a direct interaction between SEPT9 and HMGB1 in cervix cancer was reported [21]
further validating our results.
5. Conclusions
In conclusion, the analysis of the HMGB1 interactomes in prostate and ovary cancer
cells reveals new connections of HMGB1 functions to RNA processing and ribosome
biogenesis through interactions with components of the NuRD complex, THOC complex
and septins. Given the relevance of all these factors in cancer development and progression,
the interaction networks provide new insight on their role in oncogenesis.
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